DARWIN GLOBAL MANAGEMENT LTD
Q3 2026 Form 13-F

ST. HELIER
CIK 0001839209 · CRD 312512 · Exempt reporting adviser
$4.0B Reported Value Total

DARWIN GLOBAL MANAGEMENT, LTD. reports under management (AUM).

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-30
Reported value
$4.0B
Quarter over quarter
+3.9%
Holdings
5
Top-10 concentration
100.0%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Sarah Monime
CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $4.0B
Positions 5
Change in reported value +6.2%
New positions 1
Exited positions 1
Position turnover 33.3%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
5 $4.0B
Q2 2026 13F
Filed Aug 14, 2026
5 $3.8B
Q1 2026 13F
Filed May 15, 2026
6 $3.8B
Q4 2025 13F
Filed Feb 17, 2026
6 $4.9B
Q3 2025 13F
Filed Nov 14, 2025
5 $3.6B
Q2 2025 13F
Filed Aug 14, 2025
5 $2.4B
Q1 2025 13F
Filed May 15, 2025
3 $1.5B
Q4 2024 13F
Filed Feb 14, 2025
6 $1.1B
Q3 2024 13F
Filed Nov 14, 2024
5 $1.2B
Q2 2024 13F
Filed Aug 14, 2024
9 $859.5M
Q1 2024 13F
Filed May 15, 2024
12 $751.2M
Q4 2023 13F
Filed Feb 14, 2024
8 $509.5M
Q3 2023 13F
Filed Nov 14, 2023
3 $284.2M
Q2 2023 13F
Filed Aug 14, 2023
3 $611.7M
Q1 2023 13F
Filed May 15, 2023
4 $365.6M
Q4 2022 13F
Filed Feb 14, 2023
4 $160.6M
Q3 2022 13F
Filed Nov 14, 2022
2 $66.4M
Q2 2022 13F
Filed Aug 15, 2022
1 $188.2M
Q1 2022 13F
Filed May 16, 2022
1 $110.2M
Q4 2021 13F
Filed Feb 14, 2022
13 $654.6M

4 earlier quarters on file — choose one from the quarter menu above.

Top 5 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 RVMD REVOLUTION MEDICINES INC $2.2B 54.66%
2 GMAB GENMAB A/S $638.6M 16.0%
3 BLTE BELITE BIO INC $526.0M 13.18%
4 ABVX ABIVAX SA $398.2M 9.98%
5 ROIV ROIVANT SCIENCES LTD $246.7M 6.18%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings